January/February 2023 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Your Moves
Movers of the Month
Laura Wilson has been appointed as the Royal Pharmaceutical Society’s (RPS) Director for Scotland.
Laura – who is currently Policy and Practice Lead for RPS in Scotland – will drive forward professional leadership in Scotland, working with and for RPS members. Accountable for bringing national RPS policy to life for members in Scotland, while contributing to the GB-wide professional leadership agenda, she will work closely with the Scottish Pharmacy Board, senior NHS officials and other key stakeholders across the breadth of the pharmacy profession and beyond.
She joins the existing team of RPS Country Directors, which includes Elen Jones, Director for Wales and James Davies, Director for England.
Emmes has revealed that Wendy Buckland will join the company as its Chief Operating Officer, leading global operations.
Prior to taking her new role, Wendy headed PPD’s neuroscience therapeutic unit where she was responsible for strategy, client satisfaction, operational delivery, profitability and talent development, as well as oversight for all clinical development programmes in neuroscience and ophthalmology.
Insitro has announced that Philip Tagari has been appointed as Chief Scientific Officer. Philip joins the company following a 24-year career at Amgen, where he led research platforms for over a decade as Vice President, research, therapeutic discovery.
Philip joins a cross-functional team of experts in biology and technology at Insitro, part of a uniquely collaborative culture that spans the boundaries of both fields.
During his time at Amgen, Philip built and led a global organisation of over 600 scientists that delivered numerous experimental and marketed therapies in neurology, inflammation, cardiovascular disease and oncology. Throughout his career, which includes a decade at Merck and research positions at McGill University and Oxford University, he made significant contributions toward multiple first-in-class, disease-modifying, life-changing therapies.
CN Bio has appointed Paul Brooks to the role of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative role within the company’s Scientific Advisory Board. Having joined the company as Chief Business Officer in May 2022, Paul was responsible for shaping CN Bio’s commercial business, expansion strategy and overseeing accelerated growth of the company's PhysioMimix consumables, kits and services.
With over 25 years’ experience in the life sciences sector, Paul is an experienced C-suite level executive. Prior to joining CN Bio he was Head of Business Operations & Managing Director for PerkinElmer’s Horizon Discovery, where he led the strategic and operational transformation of its business units.
Almirall has announced that Mercedes Diz will assume the position of VP Corporate Strategy and will also join Almirall's Management Board. Mercedes joined Almirall in 2002 and, since 2021, has held the position of Senior Director of Corporate Strategy, leading key strategic processes and projects for Almirall and defining the priorities to achieve the company’s long-term ambition in medical dermatology.
Among her previous roles at Almirall, Mercedes has been responsible for managing commercial activities in several affiliates – Austria, Belgium, Netherlands, Nordics, Poland, Switzerland and the UK – as well as leading global commercial support functions, including Global Alliance Management & Partners and Licensing & Corporate Development.
From 2018 to 2020, Mercedes successfully led the global marketing and market access team in charge of the company’s Strategic Global Brands. During her tenure, Almirall launched its first biologic into the psoriasis market.
Ziphius Vaccines has announced the appointment of Johan Van Hoof as Chief Scientific Advisor. Johan brings a track record of utilising technology and strategic collaborations to drive vaccines research and development forward.
He recently retired from his role as Global Therapeutic Area Head for Infectious Diseases and Vaccines at Janssen.
Prior to joining the Johnson & Johnson Family of Companies, Johan gained more than 20 years of experience in the vaccine industry, having worked with Pasteur Mérieux Connaught, Chiron Vaccines and GlaxoSmithKline. During this period, he held leadership roles with increasing responsibilities, including Head at GSK Biologicals, New Product Development.
Kelso Pharma has appointed senior pharmaceutical executive, Mark Inker, as its first UK Managing Director.
A pharmaceutical company director with over 30 years’ experience in commercialisation of pharmaceutical and medical device products, Mark has built a strong track record for growing businesses in the sector.
He brings considerable management experience gained through extensive market access and directing commercial sales and marketing operations for 31 product launches.
UK pharmaceutical industry group the European Medicines Group (EMG) has elected Jessamy Baird, Sanofi UK & Ireland Country Lead as its Chair. She will be supported by newly elected co-Vice Chair Sarah Kleinpeter, Vice President and General Manager, LEO Pharma.
EMG is the collective voice of UK operating companies of 22 research-driven pharma companies headquartered in continental Europe to provide the European company perspective on health and industrial policy.
LEX Diagnostics has announced the appointment of Ed Farrell as its new Chief Executive Officer.
The company is evolving its molecular point-of-care diagnostics with a change in speed, sensitivity and cost. Ed brings over 25 years of life sciences experience gained through senior industry roles with an emphasis on medical devices and diagnostics.
Prior to joining LEX Diagnostics Ed was COO of Klay Biotech. Meanwhile, from 2013 to 2021 he served as President/COO of Quotient where he led the development and realisation of the MosaiQ platform from concept to commercialisation.
TMC Pharma Services has appointed Gordon Cameron as a Non-Executive Director to support the growth of the business.
Gordon brings 25 years’ board-level experience in in the biotech and pharmaceutical services industry. He started his career with EY, then spent several years in investment banking at Rothschild before becoming CFO, and then CEO, of FTSE-250 international vaccine company Acambis.
For the past 15 years, Gordon was CFO of Quotient Sciences, an international Contract Development and Manufacturing Organisation and Clinical Research Organisation. During his tenure, revenues grew 15-fold and Gordon led four changes of private equity ownership. In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry.
MaxCyte has appointed Patrick Balthrop Sr. to the company’s Board of Directors as non-executive director with immediate effect. Patrick is also appointed as non-executive member of the Nominating and Corporate Governance Committee.
He has more than 35 years of experience in the healthcare sector, particularly in the life sciences segments of diagnostics, life sciences tools and medical devices. He was CEO, President, and Director of Luminex Corporation for over ten years, quadrupling the company’s revenue in five years.
Prior to that he was President of Fisher Healthcare. He held also positions at Abbott Laboratories over a period of 20 years including head of Abbott Vascular and Corporate VP of Worldwide Operations for Abbott Diagnostics.
CluePoints has today announced Andy Cooper has been appointed as its new Chief Executive Officer. Cooper succeeds Co-Founder, Francois Torche, who is stepping back as CEO to focus his full attention on the strategic direction of CluePoints’ world-leading product portfolio.
Andy has 24 years of clinical trial industry and software experience at companies including Oracle and Medidata. His most recent role was at Clario, where he was General Manager for the eCOA Business Unit. His experience will be important in further accelerating the growth and scale-up of the company.
Coulter Partners has announced the appointment of Dr Hannah Musisi as Executive Director. Hannah will focus on organisational and leadership advisory services, particularly in digital health, drawing on expertise in commercial strategy, business development and growing new businesses.
Hannah brings over 20 years of experience across consulting, sales and growth in diverse sectors including energy, media and digital health. She joins Coulter Partners from her own consultancy where she provided strategic, commercial and operational advice to Digital Health start-ups and technology companies, including Digital Therapeutics and Telemedicine companies Babylon Health and Big Health.